Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab

David Chu, Michelle Stevens, Douglas Edward Gladstone

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


A 41 year old female with type I cryoglobulinemia, refractory to methylprednisolone, rituximab, and cyclophosphamide complicated by a rising serum viscosity was treated with alemtuzumab. After a cumulative dose of 1,085 mg of alemtuzumab, her serum viscosity decreased to normal. Treatment toxicity was limited to fungal esophagitis responsive to topical therapy. This case demonstrates the potential use of alemtuzumab in the treatment of refractory cryoglobulinemia.

Original languageEnglish (US)
Pages (from-to)1173-1175
Number of pages3
JournalRheumatology International
Issue number12
StatePublished - Oct 1 2007
Externally publishedYes


  • Alemtuzumab
  • Hyperviscosity
  • Type I cryoglobulinemia

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab'. Together they form a unique fingerprint.

Cite this